Shares of AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $62.30.
Several analysts have issued reports on the company. BTIG Research boosted their price objective on AtriCure from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a report on Wednesday, October 21st. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Wednesday, October 21st. Finally, Citizens Jmp upped their price target on shares of AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 21st.
Check Out Our Latest Research Report on AtriCure
AtriCure Trading Up 1.5%
Shares of AtriCure stock traded up $0.86 on Friday, reaching $56.84. 558,769 shares of the company were exchanged, compared to its average volume of 794,900. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $66.02. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of 189.47 and a beta of 1.23. The company has a current ratio of 4.33, a quick ratio of 3.29 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average price of $57.48 and a 200-day moving average price of $39.17.
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The business had revenue of $154.45 million during the quarter, compared to analyst estimates of $151.05 million. On average, analysts expect that AtriCure will post 0.44 EPS for the current year.
Insiders Place Their Bets
In other news, insider Salvatore Privitera sold 8,404 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total value of $546,260.00. Following the completion of the sale, the insider owned 134,341 shares in the company, valued at $8,732,165. This represents a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl S. Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company’s stock, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 39,026 shares of company stock worth $2,172,263. Corporate insiders own 4.00% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in AtriCure during the second quarter valued at $125,198,000. Wellington Management Group LLP boosted its position in AtriCure by 3.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after acquiring an additional 113,048 shares during the period. Dimensional Fund Advisors LP boosted its position in AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after acquiring an additional 75,862 shares during the period. Bank of America Corp DE purchased a new position in AtriCure during the 2nd quarter valued at about $24,465,000. Finally, Grandeur Peak Global Advisors LLC purchased a new position in AtriCure during the 2nd quarter valued at about $16,435,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.
Read More
- Five stocks we like better than AtriCure
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
